Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Multicenter Study to Assess the Efficacy of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP): The AGNOSTOS Trial

NCT02607202 is registered in ClinicalTrials.gov with Fondazione del Piemonte per l'Oncologia as lead sponsor.

NCT NCT02607202
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02607202 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Multicenter Study to Assess the Efficacy of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP): The AGNOSTOS Trial
Lead sponsor
Fondazione del Piemonte per l'Oncologia
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2015
Completion date
January 31, 2022
Enrollment
57 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

unknown primary tumors